Navigation Links
B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
Date:2/25/2010

BETHLEHEM, Pa., Feb. 25 /PRNewswire/ -- With calls for greater efficiency, safety and an expanded use of electronic health records shaping the healthcare environment, interoperability and systems integration are taking on added importance in the healthcare marketplace. B. Braun Medical Inc. (B. Braun) is placing greater emphasis on infusion therapy systems that seamlessly interface and interoperate with healthcare facility information systems.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

B. Braun's Infusion Pumps, DoseTrac™ Infusion Management Software and DoseLink™ Interfaces successfully completed key portions of the Healthcare Information Technology Standards Panel (HITSP), a federally-recognized Interoperability Specifications test, at the Integrating the Healthcare Enterprise 2010 Connectathon in Chicago in January.

The Connectathon is the healthcare information technology (IT) industry's largest interoperability testing event. Nearly 60 vendors tested more than 130 healthcare IT systems.

"The emphasis in the healthcare industry today is on developing healthcare systems that can interface, interoperate and have the ability to transmit patient and clinical information electronically to reduce errors and deliver more effective treatment to patients," said Scott Zaffrin, Manager, Connectivity Marketing & Operations for B. Braun Medical Inc. "Our suite of infusion system products is designed to do just that. We look forward to another opportunity to interact with healthcare professionals and demonstrate our solutions using the kind of clinical scenarios our customers face every day."

B. Braun will demonstrate the Outlook ® Safety Infusion System, DoseTrac™ and DoseLink

(B. Braun's IHE compliant HL7 interfaces) systems and its medication administration and electronic health record interoperability at the Healthcare Information and Management Systems Society's HIMSS10 Interoperability Showcase at booth 233 in the Atlanta Convention Center during the HIMSS Conference & Exhibition, March 1-4 in Atlanta.

Designed as a HIMSS Health Information Exchange (HIE)-based environment, the Showcase includes clinical scenarios enabled by the standards-based IHE technical framework and HITSP federally-recognized Interoperability Specifications.

B. Braun will demonstrate the interoperability of its DoseTrac™ Infusion Management Software, DoseLink™ Interfaces and Outlook® Safety Infusion Systems using two-way communication with numerous vendors including Cerner, Epic, GE Centricity, Draeger, Philips, Capsule and more.

B. Braun Infusion Pumps deliver critical IV medications to patients and communicate this infusion data to the company's DoseTrac™ Infusion Management Software. Infusion data is wirelessly communicated to the DoseTrac™ software, which collects and stores real-time infusion data, allowing caregivers to view it from any workstation. Its open architecture design and the use of its DoseLink™ IHE HL7 Compliant Interfaces allows it to interface with any hospital or pharmacy information management system. DoseTrac™ is the only software of its type to offer both real-time displays of infusion data as well as comprehensive retrospective reporting capabilities.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.

SOURCE B. Braun

Back to top

RELATED LINKS
http://www.bbraunusa.com

'/>"/>

SOURCE B. Braun
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
2. B. Braun Introduces WHIN(R) Safe Huber Needle
3. B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings
4. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
5. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
6. I3, the Developer of Innovative Infusion Therapy Solutions, to Present at Medtech Insight In3 Conference in Las Vegas, March 4-5, 2010
7. Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System
8. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
11. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
Breaking Medicine News(10 mins):